Raymond James analyst Steven Seedhouse downgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Outperform to Market Perform.
Beyond Air Q3 EPS $(0.43) Misses $(0.41) Estimate
Beyond Air (NASDAQ:XAIR) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.41) by 4.88 percent. This is a 48.28 percent decrease over losses of $(0.29) per share from the
